Clinical Trial: A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis

U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07693738) titled 'A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis' on April 24.

Brief Summary: The purpose of this Phase 1 study is to evaluate the safety and tolerability of a new investigational drug called SSGJ-716 in healthy adults and in participants with moderate-to-severe atopic dermatitis (AD).

The study has two parts. The first part (Single Ascending Dose, SAD) will enroll healthy adults.The second part (Multiple Ascending Dose, MAD) will enroll participants with moderate-to-severe AD.

Study Start Date: May 18

Study Type: INTERVENTIONAL

Condition: AD

Intervention: DRUG: SSGJ-716...